MX2019009559A - Administracion subcutanea de un antagonista del receptor p2y12. - Google Patents

Administracion subcutanea de un antagonista del receptor p2y12.

Info

Publication number
MX2019009559A
MX2019009559A MX2019009559A MX2019009559A MX2019009559A MX 2019009559 A MX2019009559 A MX 2019009559A MX 2019009559 A MX2019009559 A MX 2019009559A MX 2019009559 A MX2019009559 A MX 2019009559A MX 2019009559 A MX2019009559 A MX 2019009559A
Authority
MX
Mexico
Prior art keywords
receptor antagonist
subcutaneous administration
cyclopropylamino
triazolo
difluorophenyl
Prior art date
Application number
MX2019009559A
Other languages
English (en)
Inventor
Kramberg Markus
Rey Markus
Riederer Markus
BAUMANN Martine
Roux Sebastien
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2019009559A publication Critical patent/MX2019009559A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere a un antagonista del receptor P2Y12 que se selecciona a partir del grupo que consiste en butil-éster del ácido 4-((R)-2-{[6-((S)-3-metoxi-pirrolidin-1-iI)- 2-fenil-pirimidin-4-carbonil]-amino}-3-fosfono-propionil)-piperaz in-1-carboxílico, (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluoro-feni l)-ciclopropil-amino]-5-(tiopropil)-3H-[1,2,3]-triazolo-[4,5-d]-p irimidin-3-iI]-5-(2-hidroxi-etoxi)-ciclopentano-1,2-diol, y (1S,2R,3S,4R)-4-[7-[(1R,2S)-2-(3,4-difluoro-fenil)-ciclopropil-am ino]-5-(tiopropil)-3H-[1,2,3]-triazolo-[4,5-d]-pirimidin-3-iI]-ci clopentano-1,2,3-triol, o una sal farmacéutica-mente aceptable de los mismos, para usarse como un medicamento a través de la administración subcutánea o intra-dérmica.
MX2019009559A 2017-03-15 2018-03-14 Administracion subcutanea de un antagonista del receptor p2y12. MX2019009559A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017056175 2017-03-15
PCT/EP2018/056372 WO2018167139A1 (en) 2017-03-15 2018-03-14 Subcutaneous administration of a p2y12 receptor antagonist

Publications (1)

Publication Number Publication Date
MX2019009559A true MX2019009559A (es) 2019-10-15

Family

ID=61899166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009559A MX2019009559A (es) 2017-03-15 2018-03-14 Administracion subcutanea de un antagonista del receptor p2y12.

Country Status (18)

Country Link
US (1) US11179390B2 (es)
EP (1) EP3595666A1 (es)
JP (2) JP2020510043A (es)
KR (1) KR102510832B1 (es)
CN (1) CN110381947A (es)
AU (1) AU2018234056B2 (es)
BR (1) BR112019014567A2 (es)
CA (1) CA3050831A1 (es)
CL (1) CL2019002318A1 (es)
EA (1) EA201992123A1 (es)
IL (1) IL269286B2 (es)
MA (1) MA49887A (es)
MX (1) MX2019009559A (es)
PH (1) PH12019502111A1 (es)
SG (1) SG11201908128YA (es)
TW (1) TWI765002B (es)
UA (1) UA125531C2 (es)
WO (1) WO2018167139A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124073C2 (uk) 2016-09-22 2021-07-14 Ідорсія Фармасьютікалз Лтд Кристалічні форми гідрохлориду складного бутилового ефіру 4-((r)-2-{[6-((s)-3-метоксипіролідин-1-іл)-2-фенілпіримідин-4-карбоніл]-аміно}-3-фосфонопропіоніл)-піперазин-1-карбонової кислоти
JP2023532816A (ja) 2020-07-15 2023-07-31 イドーシア ファーマシューティカルズ リミテッド Ｐ２ｙ１２受容体アンタゴニストを有する水性医薬組成物
CN117616033A (zh) 2021-07-13 2024-02-27 爱杜西亚药品有限公司 4-((r)-2-{[6-((s)-3-甲氧基-吡咯烷-1-基)-2-苯基-嘧啶-4-羰基]-氨基}-3-膦酰基-丙酰基)-哌嗪-1-羧酸丁酯的合成方法
WO2023174810A1 (en) 2022-03-14 2023-09-21 Idorsia Pharmaceuticals Ltd A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870035A (en) 1970-07-17 1975-03-11 Survival Technology Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
GR861289B (en) 1985-05-20 1986-09-16 Survival Technology Injection method and apparatus with electrical blood absorbing stimulation
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
JP4662777B2 (ja) 2002-12-11 2011-03-30 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 血小板アデノシン二リン酸受容体アンタゴニストとしての２−アミノカルボニルキノリン化合物
JP4621659B2 (ja) 2003-04-09 2011-01-26 ワイス・エルエルシー ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸の誘導体およびｎ−メチル−ｄ−アスパルテート（ｎｍｄａ）受容体アンタゴニストとしてのその使用
AU2003249865A1 (en) * 2003-06-24 2005-01-21 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
EA200901473A1 (ru) 2007-05-02 2010-06-30 Портола Фармасьютиклз, Инк. Внутривенные и пероральные лекарственные формы прямого и обратимого ингибитора p2y12
US8518912B2 (en) 2007-11-29 2013-08-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as P2Y12 receptor antagonists
JP5560202B2 (ja) 2007-12-26 2014-07-23 サノフイ Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
JP5504171B2 (ja) 2007-12-26 2014-05-28 サノフイ Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
US8288385B2 (en) 2009-04-08 2012-10-16 Actelion Pharmaceuticals Ltd. 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
AU2010240527A1 (en) 2009-04-22 2011-12-01 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as P2Y12 receptor antagonists
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2585161A1 (en) 2010-06-23 2013-05-01 Stefan Kralev Medical device for self-administration of patients with acute coronary events
UA124073C2 (uk) 2016-09-22 2021-07-14 Ідорсія Фармасьютікалз Лтд Кристалічні форми гідрохлориду складного бутилового ефіру 4-((r)-2-{[6-((s)-3-метоксипіролідин-1-іл)-2-фенілпіримідин-4-карбоніл]-аміно}-3-фосфонопропіоніл)-піперазин-1-карбонової кислоти

Also Published As

Publication number Publication date
WO2018167139A1 (en) 2018-09-20
KR102510832B1 (ko) 2023-03-15
JP2020510043A (ja) 2020-04-02
TWI765002B (zh) 2022-05-21
UA125531C2 (uk) 2022-04-13
US11179390B2 (en) 2021-11-23
TW201840323A (zh) 2018-11-16
CA3050831A1 (en) 2018-09-20
KR20190124297A (ko) 2019-11-04
MA49887A (fr) 2020-06-24
BR112019014567A2 (pt) 2020-02-18
US20200129510A1 (en) 2020-04-30
PH12019502111A1 (en) 2020-03-16
AU2018234056A1 (en) 2019-10-31
EA201992123A1 (ru) 2020-02-25
AU2018234056B2 (en) 2023-05-25
IL269286A (en) 2019-11-28
IL269286B2 (en) 2023-08-01
IL269286B1 (en) 2023-04-01
CL2019002318A1 (es) 2020-01-10
CN110381947A (zh) 2019-10-25
SG11201908128YA (en) 2019-10-30
JP2023052576A (ja) 2023-04-11
EP3595666A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
PH12019502111A1 (en) Subcutaneous administration of a p2y12 receptor antagonist
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
NZ629432A (en) Heterocyclyl compounds as mek inhibitors
WO2015042078A8 (en) Substituted aminopyrimidine compounds and methods of use
PH12018500437A1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
HRP20210543T1 (hr) Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CL2013003647A1 (es) Compuestos derivados de pirrolo[2,3-d] pirimidina o pirrolo[2,3-b]piridina, inhibidores de la actividad de jak; composicion farmaceutica; utiles para el tratamiento de enfermedades autoinmunitarias, inflamatorias y de reabsorcion osea, cancer, trastornos mieloproliferativos o rechazo a trasplante de organos.
MX2013013294A (es) Inhibidores de tirosina-cinasas.
NZ627277A (en) Imidazopyrrolidinone compounds
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
MA40236A (fr) Formes cristallines de (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanpyrido[1',2':4,5]pyrazino 2,1-b][1,3]oxazépine-10-carboxamide
WO2013109972A3 (en) Therapeutic compounds
MX2016012669A (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1.
WO2015110491A3 (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
PH12018502226A1 (en) Orally disintegrating tablets
BR112019004269A2 (pt) composição farmacêutica compreendendo rosuvastatina e ezetimiba e método para sua preparação
EA201590112A1 (ru) НОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ ТВЕРДЫЕ ФОРМЫ (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-ДИФТОРФЕНИЛ)ЦИКЛОПРОПИЛАМИНО]-5-(ПРОПИЛТИО)-3H-[1,2,3]ТРИАЗОЛО[4,5-d]ПИРИМИДИН-3-ИЛ]-5-(2-ГИДРОКСИЭТОКСИ)ЦИКЛОПЕНТАН-1,2-ДИОЛА
MY175052A (en) Crystalline forms of (s) -4-amino-n- (1- (4 - chlorophenyl) - 3 - hydroxypropyl) -1- (7h - pyrrolo [2, 3-d] pyrimidi n-4-yl) piperidine-4-carboxamide
EP4257205A3 (en) Treatment of hand eczema
TN2013000483A1 (en) Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
MY169449A (en) Therapeutic treatment
NZ705994A (en) Process for preparing pemetrexed di potassium and its hydrates
WO2016117852A3 (ko) 티카그렐러 제조방법 및 이를 위한 신규한 중간체